Stratus Medical Secures $10M in Series B Funding for RF Ablation Therapy in Chronic Pain
There is a special kind of quiet confidence you only see in medtech, the kind that shows up in a sterile room at 7 a.m. while everyone else is still arguing on the internet. Chronic pain does not...
There is a special kind of quiet confidence you only see in medtech, the kind that shows up in a sterile room at 7 a.m. while everyone else is still arguing on the internet. Chronic pain does not care about hype. It cares about outcomes, workflow, and whether the tool in the physician’s hand does what it promised when the lights get bright.
Stratus Medical has been building in that weather since December 2019, out of Magnolia, Texas, about 30 minutes north of Houston George Bush Intercontinental Airport. Bret Boudousquie, Founder & CEO, teamed up with Med Venture Holdings, now Wasatch Health, to acquire the NimbusRF business assets from Biomerics and turn them into a focused interventional pain medicine company. That is not a “big idea” story. That is a “go make it real” story.
Now the capital matches the ambition. Stratus Medical just secured $10M Series B, announced February 4, 2026, led by Wasatch Health Partners Growth Fund. Stack that on top of the $25M convertible debt facility from Wasatch Health Partners Structured Capital, and you get $35M+ of runway to keep the science honest and the execution relentless. Congratulations to Bret Boudousquie, Will Pankey, VP of Sales, US, Lisa Pelletier, VP, Operations, Cody Jorgensen, Director of Marketing, and Frida Leon Olmedo, Engineer I, plus the advisory bench with Jake Wakley, Dan Higgs, and Eric Hyman.
The product names are doing a little poetry on purpose. NIMBUS RF is the flagship, a multitined expandable electrode designed to create a larger, more predictable lesion size and shape, while aiming to reduce procedure time compared to standard RF needles. Vesta RF Cannula brings the cannula side of the portfolio with FDA 510(k) clearance February 7, 2020. FDA cleared and CE marked is not marketing copy, it is the paperwork version of “prove it.”
The traction is not theoretical either. 212% revenue growth from 2020–2023, ranked 483 on the 2024 Deloitte Technology Fast 500, with current-year operating revenues exceeding $5M. Direct sales in the United States, distributors in the United Kingdom, Australia, Brazil, Spain, Ireland, France, Germany, and Italy, because pain is global and excuses do not translate well.
The Series B proceeds are pointed where they should be: completing the Stratus Medical RF Generator, completing neurovasis Basivertebral Nerve Ablation technology, expanding and protecting the patent estate, and funding clinical studies. The double-blinded, randomized, comparative trial for sacroiliac joint pain already has its first patient enrolled March 2023, led by Dr. Aaron Conger and Dr. Zachary McCormick at University of Utah PM&R. As of April 2024, the portfolio stood at 37 granted patents globally, including 5 U.S. patents.
If you sell to interventional pain physicians, hospitals, or ambulatory surgery centers, this is the part where you stop asking for innovation and start asking about predictable lesions, fewer minutes per procedure, and a team that treats regulatory, IP, and commercialization like one integrated discipline, so what do you want your next RF workflow to feel like when the patient is counting on you and the clock is not your friend.